CEO Laurent Fischer was paid $4,131,290 in fiscal year 2024, ↑ up 167.1% from fiscal year 2023, the 60th percentile of its disclosed peer group (SEC filing 0001140361-25-016005 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$4,131,290 ↑ Laurent Fischer total, FY2024 | 60th CEO pay percentile vs peers | 19:1 CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Ask our research desk, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Laurent Fischer | $691,795 | $0 | $171,363 | $2,839,252 | $415,080 | $0 | $13,800 | $4,131,290 |
| President and Chief Executive Officer | ||||||||
| Kishor Soparkar | 509,300 | 0 | 55,437 | 1,062,124 | 203,720 | 0 | 12,597 | 1,843,178 |
| Chief Operating Officer | ||||||||
| Linda Rubinstein | 499,600 | 0 | 0 | 892,685 | 199,840 | 0 | 13,800 | 1,605,925 |
| Chief Financial Officer | ||||||||
| Setareh Seyedkazemi | 497,500 | 0 | 25,190 | 867,631 | 199,000 | 0 | 9,121 | 1,598,442 |
| Chief Development Officer | ||||||||
| Rabia Ozden | 281,250 | 150,000 | 0 | 732,503 | 112,022 | 0 | 29,358 | 1,305,133 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Laurent Fischer | $4,131,290 | $1,546,477 | $2,906,639 | ↑ +2,584,813 |
| Kishor Soparkar | 1,843,178 | 903,024 | 1,346,784 | ↑ +940,154 |
| Linda Rubinstein | 1,605,925 | 2,301,333 | 111,888 | ↓ −695,408 |
| Setareh Seyedkazemi | 1,598,442 | 799,362 | 1,520,756 | ↑ +799,080 |
| Rabia Ozden | 1,305,133 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Adverum Biotechnologies's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ADVM reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses ADVM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ADVM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kishor Soparkar | Option | 7,438 | 12.9 | — |
| Laurent Fischer | Option | 10,500 | 12.9 | — |
| Laurent Fischer | Option | 52,313 | 7.5 | — |
| Linda Rubinstein | Option | 62,083 | 7.15 | — |
| Kishor Soparkar | Option | 22,500 | 7.5 | — |
| Kishor Soparkar | PSU | 14,666 | — | 68,490 |
| Rabia Ozden | Option | 2,667 | 13.5 | — |
| Setareh Seyedkazemi | Option | 11,511 | 17.3 | — |
| Setareh Seyedkazemi | Option | 43,458 | 7.15 | — |
| Rabia Ozden | Option | 44,010 | 7.15 | — |
| Laurent Fischer | Option | 2,840 | 134.4 | — |
| Kishor Soparkar | Option | 4,334 | 12.9 | — |
| Rabia Ozden | Option | 85,000 | 7.32 | — |
| Laurent Fischer | PSU | 45,333 | — | 211,705 |
| Setareh Seyedkazemi | PSU | 6,664 | — | 31,121 |
| Kishor Soparkar | Option | 45,000 | 19.9 | — |
| Laurent Fischer | Option | 200,000 | 7.15 | — |
| Laurent Fischer | Option | 110,420 | 19.9 | — |
| Laurent Fischer | Option | 16,876 | 10.9 | — |
| Laurent Fischer | Option | 18,375 | 12.9 | — |
| Linda Rubinstein | Option | 35,000 | 19.9 | — |
| Kishor Soparkar | Option | 582 | 134.4 | — |
| Linda Rubinstein | Option | 46,042 | 21 | — |
| Setareh Seyedkazemi | Option | 40,000 | 19.9 | — |
| Setareh Seyedkazemi | Option | 14,063 | 7.5 | — |
| Setareh Seyedkazemi | Option | 2,834 | 12.9 | — |
| Kishor Soparkar | Option | 64,394 | 7.15 | — |
| Kishor Soparkar | Option | 4,096 | 10.9 | — |
Adverum aligns executive financial interests with stockholders by making a significant portion of compensation variable and tied to the achievement of key financial and strategic performance objectives and stock price performance. The program is designed to attract and retain high-performing leaders, emphasize a pay-for-performance culture without encouraging excessive risk, and support strategic initiatives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Ratio (CEO : median employee) | 19 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | $212,303 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Patrick MachadoIndependent · Board Chair · Audit (Chair) · Compensation | $102,500 | — | $77,767 | — | $0 | $180,267 |
| Szilard KissNot independent | 26,224 | — | 120,669 | — | 33,150 | 180,043 |
| James ScopaIndependent · Audit · Compensation (Chair) | 65,000 | — | 59,197 | — | 0 | 124,197 |
| Scott WhitcupIndependent · Nominating and Corporate Governance · Research and Development | 60,000 | — | 59,197 | — | 0 | 119,197 |
| Dawn SvoronosIndependent · Audit · Nominating and Corporate Governance (Chair) | 60,000 | — | 59,197 | — | 0 | 119,197 |
| Mark LupherIndependent · Nominating and Corporate Governance · Research and Development | 52,500 | — | 59,197 | — | 0 | 111,697 |
| Reed TucksonIndependent · Compensation · Nominating and Corporate Governance | 52,500 | — | 59,197 | — | 0 | 111,697 |
| C. David NicholsonIndependent · Research and Development | 47,500 | — | 59,197 | — | 0 | 106,697 |
| Soo HongIndependent · Compensation | 47,500 | — | 59,197 | — | 0 | 106,697 |
| Laurent FischerEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $513,724 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $33,150 |
| Total cost of the board | $546,874 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Adverum Biotechnologies names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Adverum Biotechnologies.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ocular Therapeutics | 2025 | Pravin Dugel | $819,200 | $18,608,000 | $15,567,000 | $0 | $35,946,958 |
| 2 | MeiraGTx | 2025 | Alexandria Forbes | 840,000 | 5,823,500 | — | — | 8,330,006 |
| 3 | RAPT Therapeutics | 2024 | Brian Wong | 630,000 | 0 | 5,927,297 | 416,000 | 6,979,539 |
| 4 | Allakos | 2023 | Robert Alexander | 805,460 | 2,171,340 | 2,623,519 | 684,641 | 6,299,426 |
| 5 | EyePoint Pharmaceuticals | 2025 | Jay Duker | 696,251 | 1,610,700 | 2,604,113 | 632,700 | 5,568,352 |
| 6 | Solid Biosciences | 2025 | Alexander Cumbo | 650,988 | 2,318,275 | 1,792,397 | 0 | 5,223,442 |
| 7 | CytomX Therapeutics | 2025 | Sean McCarthy | 675,290 | 1,150,463 | 2,158,170 | 749,572 | 4,738,495 |
| 8 | Aldeyra Therapeutics | 2025 | Todd Brady | 700,000 | 0 | 3,801,379 | 189,000 | 4,704,179 |
| 9 | Adverum Biotechnologies | 2024 | Laurent Fischer | 691,795 | 171,363 | 2,839,252 | 415,080 | 4,131,290 |
| 10 | Taysha Gene Therapies | 2025 | Sean Nolan | 645,840 | 1,651,125 | 1,258,425 | 542,506 | 4,099,065 |
| 11 | Nkarta | 2025 | Paul Hastings | 674,384 | 236,250 | 1,711,957 | 344,947 | 2,978,038 |
| 12 | Allovir | 2025 | Andrew Oxtoby | 537,733 | 0 | 1,687,076 | 344,306 | 2,569,115 |
| 13 | Voyager Therapeutics | 2025 | Alfred Sandrock | 674,903 | 611,900 | 843,900 | 361,917 | 2,508,370 |
| 14 | Kodiak Sciences | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 15 | Assembly Biosciences | 2025 | Jason Okazaki | 647,500 | 661,671 | 573,574 | 585,000 | 2,482,987 |
| 16 | Lineage Cell Therapeutics | 2025 | Brian Culley | 691,800 | 0 | 882,970 | 518,900 | 2,111,170 |
| 17 | 4D Molecular Therapeutics | 2025 | David Kirn | 667,252 | 0 | 822,750 | 560,597 | 2,051,343 |
| 18 | Alector | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 19 | Generation Bio Co. | 2024 | Geoff McDonough | 655,301 | 0 | 790,358 | 360,416 | 1,808,274 |
| 20 | Syros Pharmaceuticals | 2023 | Conley Chee | 479,092 | 369,460 | 0 | 192,455 | 1,041,697 |
| 21 | Ovid Therapeutics | 2025 | Margaret Alexander | 515,000 | 24,806 | 118,466 | 350,000 | 1,022,272 |
| — | Tenaya Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Adverum Biotechnologies | not disclosed | not disclosed | not disclosed | Aon |
| 4D Molecular Therapeutics | 140% | Options 100 | not disclosed | Radford (part of the Rewards Solutions practice at Aon plc) |
| Aldeyra Therapeutics | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Alector | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allakos | not disclosed | Options 55 · RSU 45 | No | Compensia |
| Allovir | not disclosed | Option 100 | not disclosed | Aon plc |
| Assembly Biosciences | not disclosed | Options 100 | No | Alpine Rewards, LLC |
| CytomX Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| EyePoint Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| Generation Bio Co. | not disclosed | not disclosed | not disclosed | Compensia |
| Kodiak Sciences | 150% | Options 100 | not disclosed | Compensia, Inc. |
| Lineage Cell Therapeutics | not disclosed | not disclosed | not disclosed | Anderson |
| MeiraGTx | not disclosed | RSU 100 | not disclosed | Total Compensation Solutions |
| Nkarta | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Ocular Therapeutics | 145% | not disclosed | No | Aon |
| Ovid Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLP |
| RAPT Therapeutics | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Solid Biosciences | 100% | not disclosed | No | Radford (AON Hewitt) |
| Syros Pharmaceuticals | not disclosed | not disclosed | not disclosed | Compensia Inc. |
| Taysha Gene Therapies | not disclosed | not disclosed | not disclosed | Aon |
| Tenaya Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Voyager Therapeutics | 97.5% | not disclosed | No | Alpine Rewards, LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Laurent Fischer | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Executive Compensation”. As printed: 4,131,290. Filing ↗machine: r2 · c24 · span 929707–929716 |
| 2 | Section 01, Kishor Soparkar | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Executive Compensation”. As printed: 1,843,178. Filing ↗machine: r12 · c24 · span 972299–972308 |
| 3 | Section 01, Linda Rubinstein | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Executive Compensation”. As printed: 1,605,925. Filing ↗machine: r5 · c24 · span 942822–942831 |
| 4 | Section 01, Setareh Seyedkazemi | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Executive Compensation”. As printed: 1,598,442. Filing ↗machine: r9 · c24 · span 959786–959795 |
| 5 | Section 01, Rabia Ozden | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Executive Compensation”. As printed: 1,305,133. Filing ↗machine: r8 · c24 · span 955355–955364 |
| 6 | Section 07, pay ratio | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “CEO Pay Ratio”. As printed: 19 : 1. Filing ↗ |
| 7 | Section 08, Patrick Machado | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Director Compensation”. As printed: 180,267. Filing ↗machine: span 689776–689958 |
| 8 | Section 08, Szilard Kiss | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Director Compensation”. As printed: 180,043. Filing ↗machine: span 684779–684961 |
| 9 | Section 08, James Scopa | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Director Compensation”. As printed: 124,197. Filing ↗machine: span 694772–694954 |
| 10 | Section 08, Scott Whitcup | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Director Compensation”. As printed: 119,197. Filing ↗machine: span 702402–702627 |
| 11 | Section 08, Dawn Svoronos | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Director Compensation”. As printed: 119,197. Filing ↗machine: span 697444–697669 |
| 12 | Section 08, Mark Lupher | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Director Compensation”. As printed: 111,697. Filing ↗machine: span 687449–687674 |
| 13 | Section 08, Reed Tuckson | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Director Compensation”. As printed: 111,697. Filing ↗machine: span 699807–700032 |
| 14 | Section 08, C. David Nicholson | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Director Compensation”. As printed: 106,697. Filing ↗machine: span 692453–692635 |
| 15 | Section 08, Soo Hong | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Director Compensation”. As printed: 106,697. Filing ↗machine: span 682520–682702 |
| 16 | Section 08, Laurent Fischer | DEF 14A | 2025-04-28 | 0001140361-25-016005 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 17 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 18 | Section 09b board cost (computed) | Computed | — | — | Cash 513,724 + equity 0 + all other 33,150 = 546,874, summed across the director compensation table rows.machine: formula: Σ = 546,874 |
| 19 | Ocular Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053176 | CEO total compensation as printed in Ocular Therapeutics's own proxy. As printed: 35,946,958. Filing ↗machine: t128 · r3 · c15 · span 574379–574389 |
| 20 | MeiraGTx, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-052190 | CEO total compensation as printed in MeiraGTx's own proxy. As printed: 8,330,006. Filing ↗ |
| 21 | RAPT Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-14 | 0000950170-25-053517 | CEO total compensation as printed in RAPT Therapeutics's own proxy. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861 |
| 22 | Allakos, Section 10b CEO total | DEF 14A | 2024-04-23 | 0000950170-24-047043 | CEO total compensation as printed in Allakos's own proxy. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107 |
| 23 | EyePoint Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182035 | CEO total compensation as printed in EyePoint Pharmaceuticals's own proxy. As printed: 5,568,352. Filing ↗machine: r2 · c22 · span 573692–573701 |
| 24 | Solid Biosciences, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173642 | CEO total compensation as printed in Solid Biosciences's own proxy. As printed: 5,223,442. Filing ↗machine: r2 · c25 · span 472915–472924 |
| 25 | CytomX Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001140361-26-018237 | CEO total compensation as printed in CytomX Therapeutics's own proxy. As printed: 4,738,495. Filing ↗machine: r2 · c24 · span 739353–739362 |
| 26 | Aldeyra Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182099 | CEO total compensation as printed in Aldeyra Therapeutics's own proxy. As printed: 4,704,179. Filing ↗machine: span 302788–302797 |
| 27 | Adverum Biotechnologies (subject), Section 10b CEO total | DEF 14A | 2025-04-28 | 0001140361-25-016005 | CEO total compensation as printed in Adverum Biotechnologies's own proxy. As printed: 4,131,290. Filing ↗machine: r2 · c24 · span 929707–929716 |
| 28 | Taysha Gene Therapies, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-168525 | CEO total compensation as printed in Taysha Gene Therapies's own proxy. As printed: 4,099,065. Filing ↗machine: r3 · c27 · span 289105–289114 |
| 29 | Nkarta, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016403 | CEO total compensation as printed in Nkarta's own proxy. As printed: 2,978,038. Filing ↗machine: r2 · c27 · span 344226–344235 |
| 30 | Allovir, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177362 | CEO total compensation as printed in Allovir's own proxy. As printed: 2,569,115. Filing ↗machine: r2 · c27 · span 295176–295185 |
| 31 | Voyager Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050297 | CEO total compensation as printed in Voyager Therapeutics's own proxy. As printed: 2,508,370. Filing ↗machine: t9 · r1 · c47 · span 370852–370861 |
| 32 | Kodiak Sciences, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170429 | CEO total compensation as printed in Kodiak Sciences's own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068 |
| 33 | Assembly Biosciences, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170417 | CEO total compensation as printed in Assembly Biosciences's own proxy. As printed: 2,482,987. Filing ↗machine: t38 · r2 · c25 · span 1134174–1134183 |
| 34 | Lineage Cell Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191556 | CEO total compensation as printed in Lineage Cell Therapeutics's own proxy. As printed: 2,111,170. Filing ↗machine: span 377951–377960 |
| 35 | 4D Molecular Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001140361-26-017427 | CEO total compensation as printed in 4D Molecular Therapeutics's own proxy. As printed: 2,051,343. Filing ↗machine: r2 · c21 · span 356185–356194 |
| 36 | Alector, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 37 | Generation Bio Co., Section 10b CEO total | DEF 14A | 2025-04-23 | 0001558370-25-005263 | CEO total compensation as printed in Generation Bio Co.'s own proxy. As printed: 1,808,274. Filing ↗machine: r6 · c14 · span 601081–601090 |
| 38 | Syros Pharmaceuticals, Section 10b CEO total | 10-K | 2024-04-23 | 0001193125-24-105876 | CEO total compensation as printed in Syros Pharmaceuticals's own proxy. As printed: 1,041,697. Filing ↗machine: r2 · c27 · span 248160–248169 |
| 39 | Ovid Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027621 | CEO total compensation as printed in Ovid Therapeutics's own proxy. As printed: 1,022,272. Filing ↗machine: r4 · c42 · span 259572–259581 |
| 40 | Section 10a, Generation Bio Co. reciprocity | DEF 14A | — | 0001558370-25-005263 | Generation Bio Co.'s most recent proxy was read; its disclosed peer group does not include Adverum Biotechnologies. Filing ↗ |
| 41 | Section 10a, Ocular Therapeutics reciprocity | DEF 14A | — | 0001104659-26-053176 | Ocular Therapeutics's most recent proxy was read; its disclosed peer group does not include Adverum Biotechnologies. Filing ↗ |
| 42 | Section 10a, Alector reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector's most recent proxy was read; its disclosed peer group does not include Adverum Biotechnologies. Filing ↗ |
| 43 | Section 10a, Assembly Biosciences reciprocity | DEF 14A | — | 0001193125-26-170417 | Assembly Biosciences names Adverum Biotechnologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 44 | Section 10a, Allakos reciprocity | DEF 14A | — | 0000950170-24-047043 | Allakos's most recent proxy was read; its disclosed peer group does not include Adverum Biotechnologies. Filing ↗ |
| 45 | Section 10a, Kodiak Sciences reciprocity | DEF 14A | — | 0001193125-26-170429 | Kodiak Sciences's most recent proxy was read; its disclosed peer group does not include Adverum Biotechnologies. Filing ↗ |
| 46 | Section 10a, Lineage Cell Therapeutics reciprocity | DEF 14A | — | 0001193125-26-191556 | Lineage Cell Therapeutics names Adverum Biotechnologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 47 | Section 10a, Voyager Therapeutics reciprocity | DEF 14A | — | 0001104659-26-050297 | Voyager Therapeutics names Adverum Biotechnologies in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat